Eab Lacosamide Pharmacokinetics 00 Low protein binding(<15%) Metabolized by CyP2C19 Half-life 13 hours o000oc0= Adverse effects Common -sedation dizziness, nausea, ataxia nystagmus Rare- PR interval prolongation Euphoria, especially at 800 mg dose KENTUCKY College of Pharmacy
Lacosamide • Pharmacokinetics – Low protein binding (<15%) – Metabolized by CYP2C19 – Half-life 13 hours • Adverse effects – Common – sedation, dizziness, nausea, ataxia, nystagmus – Rare – PR interval prolongation – Euphoria, especially at 800 mg dose
Eab EZogabine/Retigabine Opens voltage-gated potassium channels " Enhances the outgoing, M-type potassium current Repolarizes the membrane back towards resting o000oc0= potential and suppressing repetitive firing ax. May also augment GABA-mediated currents Indicated for adjunctive treatment of partial- onset seizures KENTUCKY College of Pharmacy
Ezogabine/Retigabine • Opens voltage-gated potassium channels • Enhances the outgoing, M-type potassium current – Repolarizes the membrane back towards resting potential and suppressing repetitive firing • May also augment GABA-mediated currents • Indicated for adjunctive treatment of partialonset seizures
Eab EZogabine/Retigabine Pharmacokinetics 00 Excreted renally Carbamazepine and phenytoin decrease ezogabine Adverse effects o000oc0= Somnolence. dizziness, tremor Confusion(9%), hallucinations(2%), psychosis(1%) Urinary retention 2% QT interval prolongation KENTUCKY College of Pharmacy
Ezogabine/Retigabine • Pharmacokinetics – Excreted renally – Carbamazepine and phenytoin decrease ezogabine • Adverse effects – Somnolence, dizziness, tremor – Confusion (9%), hallucinations (2%), psychosis (1%) – Urinary retention 2% – QT interval prolongation
EZogabine/Retigabine :· FDA warning4/26/13 o". Pigment changes in the retina Blue skin discoloration Lips, nail beds face legs, sclera, conjunctiva Average of 4 years of treatment Recommendation: baseline and periodic a. eye exams with visual acuity testing and a: dilated fundus photography KENTUCKY College of Pharmacy
Ezogabine/Retigabine • FDA warning 4/26/13 • Pigment changes in the retina • Blue skin discoloration – Lips, nail beds, face legs, sclera, conjunctiva – Average of 4 years of treatment • Recommendation: baseline and periodic eye exams with visual acuity testing and dilated fundus photography
Eab Ezogabine/ retigabine 00 Discoloration AE-Lips o000oc0= KENTUCKY College of Pharmacy
Ezogabine/Retigabine